Literature DB >> 19941173

Staging neurological disorders: expressions of cognitive and motor disorder.

Trevor Archer1, Richard M Kostrzewa.   

Abstract

In neurologic disorders, there are progressive losses in regional brain structural integrity, circuitry, and neuronal process that threaten individuals' ability to express functional capacity at several levels of severity. The classification of (a) patients on the basis of diagnosis, risk prognosis, and intervention outcome forms the basis of clinical staging and (b) laboratory animals on the basis of animal model of brain disorder, extent of insult and dysfunctional expression, provides the components for the clinical staging and preclinical staging, respectively, of the disease state with certain associated epidemiological, biological, and genetic characteristics. The investigation of epigenetics and biomarkers is intrinsic to any analysis of the progressive nature of the neurogenerative disorders, in the present account disorders relating to Alzheimer's disease, Parkinson's disease, depression, and diabetes.

Entities:  

Mesh:

Year:  2009        PMID: 19941173     DOI: 10.1007/s12640-009-9134-x

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  13 in total

1.  Alzheimer's disease Braak Stage progressions: reexamined and redefined as Borrelia infection transmission through neural circuits.

Authors:  Alan B MacDonald
Journal:  Med Hypotheses       Date:  2006-11-17       Impact factor: 1.538

2.  Dopamine controls persistence of long-term memory storage.

Authors:  Janine I Rossato; Lia R M Bevilaqua; Iván Izquierdo; Jorge H Medina; Martín Cammarota
Journal:  Science       Date:  2009-08-21       Impact factor: 47.728

3.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

Review 4.  Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Russell W Brown; Przemyslaw Nowak; Ryszard Brus
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 5.  Neurodegenerative disorders associated with diabetes mellitus.

Authors:  Michael Ristow
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

6.  Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort.

Authors:  J Zaccai; C Brayne; I McKeith; F Matthews; P G Ince
Journal:  Neurology       Date:  2008-03-25       Impact factor: 9.910

7.  Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population.

Authors:  George M Savva; Julia Zaccai; Fiona E Matthews; Julie E Davidson; Ian McKeith; Carol Brayne
Journal:  Br J Psychiatry       Date:  2009-03       Impact factor: 9.319

Review 8.  Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.

Authors:  Victor A Gault; Peter R Flatt; Finbarr P M O'Harte
Journal:  Biochem Biophys Res Commun       Date:  2003-08-22       Impact factor: 3.575

Review 9.  Population-based neuropathological studies of dementia: design, methods and areas of investigation--a systematic review.

Authors:  Julia Zaccai; Paul Ince; Carol Brayne
Journal:  BMC Neurol       Date:  2006-01-09       Impact factor: 2.474

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  2 in total

1.  Animal models as tools to investigate antidiabetic and anti-inflammatory plants.

Authors:  Mohamed Eddouks; Debprasad Chattopadhyay; Naoufel Ali Zeggwagh
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-29       Impact factor: 2.629

2.  Cognitive fluctuations in connection to dysgraphia: a comparison of Alzheimer's disease with dementia Lewy bodies.

Authors:  Emanuela Onofri; Marco Mercuri; Giuseppe Donato; Serafino Ricci
Journal:  Clin Interv Aging       Date:  2015-03-26       Impact factor: 4.458

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.